Medical Condition News

RSS

Research focuses on HER2 cancers

As scientists continue to map breast cancer's complex genetic makeup, research at Michigan State University could lead to better diagnoses and new treatment targets.

21 Sep 2012

Childhood emotional neglect may increase risk of stroke in later adulthood

The results from a new study by neurological researchers from the Rush Alzheimer's Disease Center at Rush University Medical Center suggest that people who were emotionally neglected as children may have a higher risk of stroke in later adulthood.

21 Sep 2012

Biovest seeks EMA approval for BiovaxID to treat non-Hodgkin's lymphoma

Biovest International, Inc., a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc., today reported milestone achievements advancing BiovaxID, Biovest's personalized cancer vaccine for the treatment of non-Hodgkin's lymphoma, including a recently conducted regulatory meeting with the European Medicines Agency (EMA) and the appointment of a key contributor to the Human Genome Project to its Scientific Advisory Board.

21 Sep 2012

Study of spinal injury data may help surgeons treat injured soldiers or civilians

Spinal injuries are among the most disabling conditions affecting wounded members of the U.S. military. Yet until recently, the nature of those injuries had not been adequately explored.

21 Sep 2012

First extensive analysis of Allen Human Brain Atlas

Scientists at the Allen Institute for Brain Science reported in the latest issue of the journal Nature that human brains share a consistent genetic blueprint and possess enormous biochemical complexity. The findings stem from the first deep and large-scale analysis of the vast data set publicly available in the Allen Human Brain Atlas.

21 Sep 2012

FDA approves Acton’s AEROSPAN sNDA to treat asthma

Acton Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved the sNDA (Supplemental New Drug Application) for AEROSPAN (flunisolide HFA, 80 mcg) Inhalation Aerosol, a hydrofluoroalkane (HFA) orally inhaled corticosteroid indicated for the maintenance treatment of asthma as a prophylactic therapy in adult and pediatric patients 6 years of age and older.

21 Sep 2012

Data from Navidea’s Lymphoseek Phase 3 studies on solid tumors to be presented at ESSO

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that data from its completed Phase 3 Lymphoseek studies in breast cancer and melanoma are being presented at the 32nd Congress of the European Society of Surgical Oncology (ESSO) in Valencia, Spain, from September 19-21, 2012.

21 Sep 2012

Itrim programme effectively reduces weight among obese people

Anyone who wants to lose weight has a wide variety of diets to choose from, but knowledge of what works is often poor. Researchers at Karolinska Institutet and Uppsala University have now evaluated a Swedish commercial weight loss programme called Itrim, and found it to be effective. After one year, participants had lost 11 kg on average.

21 Sep 2012

St. Jude Medical’s Eon family of neurostimulators receives European CE Mark approval

St. Jude Medical, Inc., a global medical device company, today announced it has received European CE Mark approval of its Eon family of neurostimulators for patients with intractable chronic migraine. Unveiled at the European Headache and Migraine Trust International Congress in London, this approval includes the Eon Mini neurostimulator, which is the world's smallest rechargeable neurostimulator with the longest-lasting battery in its class, and the Eon and EonC neurostimulators.

21 Sep 2012

Newly formed emotional memories can be erased from the human brain

Newly formed emotional memories can be erased from the human brain. This is shown by researchers from Uppsala University in a new study now being published by the academic journal Science. The findings may represent a breakthrough in research on memory and fear.

21 Sep 2012

Positive results from Galleon GAL-021 second Phase I study on respiratory depression

Galleon Pharmaceuticals, a leader in the development of novel medicines to treat breathing control disorders, today announced that results from a second Phase I clinical study of its investigational drug GAL-021 confirmed previous findings that the drug has dose-dependent effects on respiration.

21 Sep 2012

Hypertonic solution effective in reducing inflammation

Research carried out at The University of Manchester has found further evidence that a simple solution, which is already used in IV drips, is an effective treatment for reducing inflammation.

From The University of Manchester 21 Sep 2012

Systems biologist to pursue research into next-generation genome sequencing technology

Systems biologist Edward Marcotte has received a $2.5 million grant from the National Institutes of Health to pursue cutting-edge research in the area of genome sequencing technology.

21 Sep 2012

Researchers use nanoparticles to deliver drugs to mitochondria within cells

Nanoparticles have shown great promise in the targeted delivery of drugs to cells, but researchers at the University of Georgia have refined the drug delivery process further by using nanoparticles to deliver drugs to a specific organelle within cells.

21 Sep 2012

MiR-34a plays a key role in obesity

Scientists have identified a key molecular player in a chain of events in the body that can lead to fatty liver disease, Type II diabetes and other metabolic abnormalities associated with obesity. By blocking this molecule, the researchers were able to reverse some of the pathology it caused in obese mice.

21 Sep 2012

Amgen receives FDA approval for Prolia to treat bone loss in men with osteoporosis

Amgen today announced the U.S. Food and Drug Administration (FDA) approved a new indication for Prolia (denosumab) as a treatment to increase bone mass in men with osteoporosis at high risk for fracture.

21 Sep 2012

Cytochroma commences CTAP101 phase 3 study in secondary hyperparathyroidism

Cytochroma today announced the initiation of a phase 3 study of CTAP101 capsules in patients with secondary hyperparathyroidism (SHPT), stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency.

21 Sep 2012

Institute for Translational Medicine and Therapeutics' 2012 symposium be held from Oct. 16-17

The Institute for Translational Medicine and Therapeutics' 7th Annual International Symposium (ITMAT) will be held October 16 and 17 at the Perelman School of Medicine, University of Pennsylvania.

20 Sep 2012

PNAS: Ras proteins bring tension to the phosphate chain

Proteins accelerate certain chemical reactions in cells by several orders of magnitude. The molecular mechanism by which the Ras protein accelerates the cleavage of the molecule GTP and thus slows cell growth is described by biophysicists at the Ruhr-Universit-t Bochum led by Prof. Dr. Klaus Gerwert in the Online Early Edition of the journal PNAS.

20 Sep 2012

Department of Psychiatry announces opening of NYU Langone's Military Family Clinic

The Department of Psychiatry is pleased to announce the opening of the Military Family Clinic at NYU Langone Medical Center, the first clinic of its kind in New York City to provide important mental health and clinical services for both returning veterans and their supportive families.

20 Sep 2012

Medical Condition News

Research focuses on HER2 cancers

Childhood emotional neglect may increase risk of stroke in later adulthood

Biovest seeks EMA approval for BiovaxID to treat non-Hodgkin's lymphoma

Study of spinal injury data may help surgeons treat injured soldiers or civilians

First extensive analysis of Allen Human Brain Atlas

FDA approves Acton’s AEROSPAN sNDA to treat asthma

Data from Navidea’s Lymphoseek Phase 3 studies on solid tumors to be presented at ESSO

Itrim programme effectively reduces weight among obese people

St. Jude Medical’s Eon family of neurostimulators receives European CE Mark approval

Newly formed emotional memories can be erased from the human brain

Positive results from Galleon GAL-021 second Phase I study on respiratory depression

Hypertonic solution effective in reducing inflammation

Systems biologist to pursue research into next-generation genome sequencing technology

Researchers use nanoparticles to deliver drugs to mitochondria within cells

MiR-34a plays a key role in obesity

Amgen receives FDA approval for Prolia to treat bone loss in men with osteoporosis

Cytochroma commences CTAP101 phase 3 study in secondary hyperparathyroidism

Institute for Translational Medicine and Therapeutics' 2012 symposium be held from Oct. 16-17

PNAS: Ras proteins bring tension to the phosphate chain

Department of Psychiatry announces opening of NYU Langone's Military Family Clinic

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News